NCT07398534 (BALPIC) is a NA clinical trial of Professional Wound Care in Wound Dehiscence, sponsored by Ilker Uckay.

Who is sponsoring NCT07398534?

NCT07398534 is sponsored by Ilker Uckay.

What drugs are being tested in NCT07398534?

Interventions in NCT07398534: Professional Wound Care.

What condition does NCT07398534 study?

NCT07398534 studies Wound Dehiscence, Wound.

Is NCT07398534 still recruiting?

NCT07398534 is currently active, enrolled. Last updated 10 February 2026.

Last reviewed 2026-02-10 · How we verify

NCT07398534: BALPIC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PICO Negative Pressure for Uninfected Foot Ulcers and Wound Dehiscence (BALPIC)

Active, enrolled NA Last updated 10 February 2026

What this trial tests

NA trial testing Professional Wound Care in Wound Dehiscence in 300 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

29 January 2026

Primary endpoint
31 December 2027

30 June 2028

Quick facts

Lead sponsor	Ilker Uckay
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	300
Start date	29 January 2026
Primary completion	31 December 2027
Estimated completion	30 June 2028
Sites	1 location across Switzerland

Drugs / interventions tested

Professional Wound Care

Conditions studied

Wound Dehiscence — all drugs for Wound Dehiscence →
Wound — all drugs for Wound →

Sponsor

Ilker Uckay

Who can join

Adults 18 to 120, any sex, with Wound Dehiscence or Wound. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators compare negative pressure wound therapy (NPWT) using the PICO 7 system versus professional wound debridement alone in adult orthopedic patients with acute, non-infected wound dehiscence or diabetic foot ulcers. Patients are randomized 1:1 to either PICO therapy (minimum 7 days, up to 42 days) or standard wound care (professional debridement without NPWT). The primary outcome is wound closure without surgical revision at Day 42. The trial is stratified for diabetic foot ulcers to enable subgroup analysis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Wound Dehiscence

Currently open trials in the same condition.

NCT06337292 — Incisional Negative Pressure Wound Therapy to Reduce Infection and Complications in High-Risk Fractures · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07398534 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ilker Uckay
Last refreshed: 10 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07398534.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing